Loading
A phase 2 trial of Alpelisib and Fulvestrant in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting.
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer is a phase 2 interventional study registered as NCT04524000 by Novartis Pharmaceuticals, with 24 participants enrolled, started 2021-01-08 and due to reach its primary completion in 2027-02-26. Interventions recorded: Alpelisib and Fulvestrant.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Fulvestrant and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Fulvestrant and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Novartis and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Novartis and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Alpelisib, Advanced Accelerator Applications (Novartis), PI3K, AKT and mTOR inhibitors, Fulvestrant and the tag pipeline.
Shares PI3K, AKT and mTOR inhibitors, Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.